Make sure you leave time in your SLAS2024 schedule to attend the Ignite Theater track on the theme ‘Innovation & technology: from lab to patient’. The programme, curated by DDW and sponsored by Integra Biosciences and Hamamatsu Corporation, will feature leading research from… Read More
The Federation of American Scientists (FAS) has published five policy recommendations to address the challenges of artificial intelligence (AI) in life sciences. The Bio X AI policy recommendations address the need for oversight of biodesign AI tools, biosecurity screening of synthetic DNA and guidance on biosecurity… Read More
The line-up of speakers is now confirmed for the SLAS2024 Ignite Theater: ‘Innovation & technology: from lab to patient’, curated by DDW and sponsored by Integra Biosciences and Hamamatsu Corporation. The event will take place on 5 and 6 February 2024 at SLAS in Boston, and will present… Read More
Andrew Busey, Co-Founder, Form Bio, discusses why vertical AI is set to reshape the cell and gene therapy sector. The once-fictional artificial intelligence (AI) depicted in literature and movies has transitioned into a tangible and easily accessible tool in our modern world. General AI tools such as ChatGPT have… Read More
Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The phage lysin-based platform – using artificial intelligence (AI) – has attracted a significant €4 million investment from Boehringer Ingelheim Venture… Read More
Dr Robert Scoffin, CEO, and Tim Cheeseright, Chief Technology Officer, at Cresset, explore the importance of flexible solutions for future-proofing drug discovery. The ability to respond to changes in patient and customer needs is a constant challenge in the pharmaceutical industry, with ever-evolving requirements influencing even… Read More
An international research team is the first to use artificial intelligence (AI) analysis to identify dual-purpose target candidates for the treatment of cancer and ageing. Researchers from the University of Oslo, University of Chicago Pritzker School of Medicine, and Insilico Medicine used Insilico’s AI target discovery… Read More
Listen to this article on the DDW Podcast: Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Over 19 million1 hearts succumb to cardiovascular disease yearly, while around 10 million2 lives are claimed by cancer… Read More
Listen to this article on the DDW Podcast: DenovAI is the second start-up to launch from the global pharma consortium AION Labs – an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. DDW Editor… Read More
Over the past several years, Dr Jo Varshney, Founder of VeriSIM Life, has front-led numerous collaborative engagements with a host of biopharma companies, government agencies, academic/medical institutes and industry innovators. Here, she discusses with DDW’s Megan Thomas the impact of AI and ML on the drug discovery process. MT:… Read More
The UK TechBio sector is thriving, according to a new report, with a growing number of companies pioneering ground-breaking products and services. A BioIndustry Association (BIA) report lists the widespread adoption of artificial intelligence (AI) and machine learning (ML), the advancement of gene editing technologies, the… Read More
The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire… Read More
Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumour cancers. The data will be presented at the Society for Immunotherapy of… Read More
Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More
Evozyne has closed an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. “In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability. Our next… Read More
Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More
